👀 Copy Legendary Investors' Portfolios in One ClickCopy For Free

Pre-Open Stock Movers 04/20: AlloVir, I-Mab Biopharma Gain; Netflix Plunges (more...)

Published 20/04/2022, 11:26 pm
DIS
-
TEVA
-
IBM
-
ELV
-
NFLX
-
LRN
-
ROKU
-
SPOT
-
IMAB
-
ALVR
-

Pre-Open Stock Movers:

Netflix (NASDAQ:NFLX) 28% LOWER; Q1 global streaming subscribers fell 200k versus an expected gain of 2.5 million. Q1 EPS was $3.53, versus the consensus of $2.90. Revenue was $7.87 billion versus the consensus estimate of $7.93 billion. Netflix sees Q2 2022 EPS of $3.00, versus the consensus of $3.01. Netflix sees Q2 2022 revenue of $8.05 billion, versus the consensus of $8.21 billion. The company sees Q2 global streaming paid net additions of -2 million, versus the consensus of 2.4 million.

AlloVir (ALVR) 25% HIGHER; FDA Grants RMAT Designation for Posoleucel

I-Mab Biopharma (IMAB) 17% HIGHER; is exploring options including a sale amid takeover interest, Bloomberg reported.

Roku , Inc. (NASDAQ:ROKU) 7% LOWER; falls on Netflix's results, which could be an ominous sign for Roku's results.

The Walt Disney Company (NYSE:DIS) 5% LOWER; falls on Netflix's results, which could be ominous for Disney+ numbers.

Teva (TEVA) 4% LOWER; The company and MedinCell announced that the FDA has issued a Complete Response Letter regarding the New Drug Application (NDA) for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia

Spotify (NYSE:SPOT) 4% LOWER; falls on Netflix's results.

Stride Inc. (LRN) 4% HIGHER; reported Q3 EPS of $1.02, versus the consensus of $0.84. Revenue was $421.7 million versus the consensus estimate of $411.12 million. Stride Inc. sees FY2022 revenue of $1.645-1.66 billion, versus the consensus of $1.63 billion

Anthem (NYSE:ANTM) (ANTM) 3% HIGHER; posted Q1 EPS of $8.25, versus the consensus of $7.81. Revenue was $37.9 billion versus the consensus of $37.42 billion. Anthem sees FY2022 EPS of $28.40, versus the consensus of $28.48

IBM (NYSE:IBM) 2% HIGHER; Q1 EPS was reported at $1.40, $0.02 better than the analyst estimate of $1.38. Revenue was $14.2 billion versus the consensus estimate of $13.85 billion. The company sees revenue growth for the year at the high end of its model.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.